Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues

Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues

Objective: The therapeutic effect of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with epithelial ovarian cancer (EOC) with somatic BRCA mutations is consistent with that observed in patients with germline BRCA mutations, indicating the importance of detecting both germline and somatic...

Full description

Bibliographic Details
Main Authors:	Eun Taeg Kim, Ha Eun Jeong, Hyung Joon Yoon, Ki Hyung Kim, Dong Soo Suh
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Series:	Taiwanese Journal of Obstetrics & Gynecology
Subjects:	BRCA Epithelial ovarian cancer Genetic counseling Next generation sequencing Poly(ADP-Ribose) polymerase inhibitors Sanger sequencing
Online Access:	http://www.sciencedirect.com/science/article/pii/S1028455922003448

Similar Items

Targeting <i>BRCA</i> Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
by: Emanuel Nicolas, et al.
Published: (2018-12-01)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
by: Kyung Jin Eoh, et al.
Published: (2020-03-01)

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
by: Andrew D. Simmons, et al.
Published: (2020-03-01)

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
by: Ji Hyun Oh, et al.
Published: (2023-11-01)

PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment
by: Sarah Johnson, et al.
Published: (2022-05-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
by: Tingting Du, et al.
Published: (2022-07-01)

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib
by: Riko Ikeda, et al.
Published: (2024-03-01)

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape
by: Ashaar Al-Akhras, et al.
Published: (2024-01-01)

High Poly(ADP-Ribose) Polymerase Expression Does Relate to Poor Survival in Solid Cancers: A Systematic Review and Meta-Analysis
by: Nishant Thakur, et al.
Published: (2021-11-01)

Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review
by: Ximu Sun, et al.
Published: (2021-12-01)

Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under <i>Parg</i> Deficiency
by: Yuki Sonoda, et al.
Published: (2020-04-01)

ADP-Ribosylation as Post-Translational Modification of Proteins: Use of Inhibitors in Cancer Control
by: Palmiro Poltronieri, et al.
Published: (2021-10-01)

Inhibiting poly(ADP-ribosylation) improves axon regeneration
by: Alexandra B Byrne, et al.
Published: (2016-10-01)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
by: Amelia Barcellini, et al.
Published: (2021-10-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

Fused in Sarcoma (FUS) in DNA Repair: Tango with Poly(ADP-ribose) Polymerase 1 and Compartmentalisation of Damaged DNA
by: Maria V. Sukhanova, et al.
Published: (2020-09-01)

What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib
by: Daniel P. Petrylak, et al.
Published: (2022-08-01)

Correlation between serum level of PARP1 and vascular calcification in hemodialysis patients
by: Hui Zhang, et al.
Published: (2023-10-01)

PARP12 is required for mitochondrial function maintenance in thermogenic adipocytes
by: Fan Hu, et al.
Published: (2022-12-01)

Disrupting Poly(ADP-ribosyl)ating Pathway Creates Premalignant Conditions in Mammalian Liver
by: Yaroslava Karpova, et al.
Published: (2023-12-01)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
by: Daniel Harrision, et al.
Published: (2020-08-01)

Poly(ADP-ribosyl)ation of p53 In Vitro and In Vivo Modulates Binding to its DNA Consensus Sequence
by: Cynthia M. Simbulan-Rosenthal, et al.
Published: (2001-01-01)

Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
by: Young Ju Suh, et al.
Published: (2022-03-01)

Poly(ADP-ribose) Polymerase 1 Mediates Rab5 Inactivation after DNA Damage
by: Masato Mashimo, et al.
Published: (2022-07-01)

Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
by: Xiao-Fei Chang, et al.
Published: (2021-10-01)

Feasibility of <i>BRCA1/2</i> Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series
by: Rossella Bruno, et al.
Published: (2021-06-01)

Selective adjuvant radiation therapy for distant lymph node metastasis in patients with stage 4B epithelial ovarian cancer: a case series
by: Eun Taeg Kim, et al.
Published: (2023-12-01)

PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer
by: Katarzyna Rygiel
Published: (2019-11-01)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
by: Emad Matanes, et al.
Published: (2021-10-01)

Changes in NAD/ADP-ribose metabolism in rectal cancer
by: L. Yalcintepe, et al.
Published: (2005-03-01)

A Double-Edged Sword: The Two Faces of PARylation
by: Mincheol Kang, et al.
Published: (2022-08-01)

3-Aminobenzamide Blocks MAMP-Induced Callose Deposition Independently of Its Poly(ADPribosyl)ation Inhibiting Activity
by: Brian D. Keppler, et al.
Published: (2018-12-01)

Next generation sequencing (NGS): a golden tool in forensic toolkit
by: Sanaa M. Aly, et al.
Published: (2016-07-01)

PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil
by: Aknar FC Calabrich, et al.
Published: (2023-04-01)

Cytotoxicity of the Sesquiterpene Lactone Spiciformin and Its Acetyl Derivative against the Human Leukemia Cell Lines U-937 and HL-60
by: Ester Saavedra, et al.
Published: (2020-04-01)

Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase
by: Divakar Vishwanath, et al.
Published: (2022-01-01)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
by: Laetitia Collet, et al.
Published: (2022-01-01)

Kynurenine–PARP-1 Link Mediated by MicroRNA 210 May Be Dysregulated in Pulmonary Hypertension
by: Alperen Emre Akgun, et al.
Published: (2022-05-01)

Neobaicalein, a flavonoid from the Scutellaria litwinowii Bornm. & Sint. ex Bornm. induced apoptosis in human leukemic cell lines
by: Seyed Ahmad Emami, et al.
Published: (2023-03-01)

Involvement of poly(ADP-ribose) polymerase-1 in development of spinal cord injury in Chinese individuals: a Chinese clinical study
by: Meng Q, et al.
Published: (2017-12-01)